Mensa Guide
Updated Antimicrobial Therapy
Free · In‑App Purchases
Mensa Guide is a comprehensive antimicrobial reference designed to support optimal therapeutic decision-making in infectious diseases. Content is structured for rapid access to key information, while allowing seamless exploration of additional details through inline notes.
• Tap on any word in the text to navigate to another entry, check abbreviations, view explanatory notes, open clinical calculators, or access bibliographic references.
• Search directly from almost all screens using clinically relevant criteria, or use full-text search for more specific queries.
• Filter and explore more than 800 pathogens according to microbiological and clinical characteristics.
• Use built-in calculators to estimate serum antibiotic concentrations, glomerular filtration rate, and many more additional clinical parameters and validated scores.
• Rely on continuously updated content, regularly reviewed to reflect evolving resistance patterns, emerging pathogens and antimicrobials, epidemiological trends, and new evidence or treatment guidelines published in leading medical journals.
Note: use of the Mensa Guide requires an annual subscription of $19.99 or a monthly subscription of $1.99 (price may vary by region), with a 30-day free trial period. A subscription allows the use of the Mensa Guide on macOS, iPhone and iPad platforms.
--
About auto-renewing subscriptions:
– An in-app subscription is one month for $1.99 or one year for $19.99.
– Payment will be charged to your iTunes Account at confirmation of purchase.
– Subscriptions automatically renew unless auto-renew is turned off at least 24-hours before the end of the current period.
– Your account will be charged for renewal within 24-hours prior to the end of the current period for $1.99 or $19.99.
– Subscriptions may be managed by the user and auto-renewal may be turned off by going to the user's Account Settings after purchase.
– Any unused portion of a free trial period, if offered, will be forfeited when the user purchases a subscription to that publication, where applicable.
Terms & Conditions: http://www.garmenmed.com/terms.html
--
Disclaimer:
This app is not intended for the general public but for health care professionals. Although we make every effort to ensure that the data is accurate, we are not responsible for any errors or omissions that the app may contain. The application of the information provided in a particular situation remains the sole responsibility of the health care professional.
--
We would love to hear your suggestions, recommendations or corrections. Contact us at mensaguide@garmenmed.com
more • Added Dermatophilus congolensis (under Pathogens).
• Changes in azithromycin, aztreonam/avibactam, cefepime/taniborbactam, cefiderocol, colistin, isoniazid. Enterobacter, Mycobacterium chelonae, Pseudomonas aeruginosa, Shigella, Streptococcus pneumoniae; CMV, EBOV, Mpox, SARS-CoV-2. Encephalitis. Exacerbations of COPD. Facial palsy. Peritonitis. Treatment of β-lactam-resistant Enterobacterales infections.
26.21 4d ago
Changes in amphotericin B deoxycholate, bictegravir, daptomycin, tecovirimat. Butyricimonas, CoNS, Escherichia coli, Gardnerella, Haemophilus influenzae, Mycobacterium tuberculosis, Mycoplasma pneumoniae, Shewanella, Staphylococcus aureus, Streptococcus agalactiae; Arthrographis kalrae, Candida, Trichophyton; LASV, MPXV, SARS-CoV-2, WNV; Sarcoptes scabiei, Schistosoma. Acute meningitis. β-lactam-resistant Enterobacterales infections. Infective endocarditis. Infections of the eyelid. Sepsis and septic shock. Infections in solid organ transplant recipients (prevention). Influenza vaccination. RSV prevention.
26.20 May 16
Changes in anidulafungin, bedaquiline, ganciclovir, imipenem/relebactam, micafungin, omadacycline, pretomanid, voriconazole. Clostridioides dificile, CoNS, Gordonia, Mycobacterium kansasii, Mycobacterium tuberculosis, Paenibacillus, Staphylococcus aureus; Aspergillus, Cryptococcus neoformans and C. gattii; HIV, Orthohantavirus, RSV, YFV. Brain abscess. Infections of the spine. Respiratory infections in cystic fibrosis. Sepsis and septic shock. Sinusitis. Recurrent urinary tract infection. Surgical site infection (prophylaxis).
26.19 May 10
Changes in cefiderocol, colistin, gepotidacin, imipenem/relebactam, lenacapavir, olorofim. Bacteroides, Citrobacter, Enterococcus, Providencia, Staphylococcus aureus, Streptococcus agalactiae; Candida; dengue, NiV, rhinovirus, RSV, SARS-CoV-2. Guillain-Barré syndrome. Pleural effusion of infectious origin. Sepsis and septic shock. Malaria (prevention). Surgical site infection (prevention).
26.18 May 3
• Added the DENOVi score (E. faecalis bacteremia).
• Changes in amoxicillin, amoxicillin/clavulanate, cabotegravir, imipenem/relebactam, isavuconazole, linezolid, meropenem/vaborbactam, posaconazole, sulbactam/durlobactam, voriconazole. Clostridioides difficile, Enterococcus, Escherichia coli, Leptospira, Staphylococcus aureus, Streptobacillus moniliformis; Aspergillus, Sporothrix; influenza; Plasmodium falciparum. Cervicitis. Exacerbations of COPD. Prosthetic joint infection. Treatment of β-lactam-resistant Enterobacterales infections. COVID-19 vaccination. Influenza (chemoprophylaxis). Infections in solid organ transplant recipients (prevention).
26.17 Apr 26
Changes in amoxicillin/clavulanate, amphotericin B (liposomal and deoxycholate), cabotegravir, ceftazidime/avibactam, posaconazole, quinolones, rilpivirine. Klebsiella, Pseudomonas aeruginosa; Aspergillus, Candida, Cryptococcus neoformans; Trypanosoma cruzi. Bacterial prostatitis. Cystitis. Infective endocarditis. Osteomyelitis. Prosthetic joint infection. Skin, subcutaneous tissue, and fascia infections. Toxic shock syndrome. Chikungunya vaccination. Dengue vaccination. Human papillomavirus vaccination. Infections in neutropenic patients (prevention). Pertussis prevention. Pertussis vaccination. RSV vaccination.
26.16 Apr 20
Changes in aztreonam/avibactam, bedaquiline, clofazimine, contezolid, dihydroartemisinin/piperaquine, glycopeptides, linezolid, meropenem/vaborbactam, molnupiravir, nirmatrelvir/ritonavir, penicillins, rifabutin. Acinetobacter, Klebsiella, Pseudomonas aeruginosa; Candida; influenza, MPXV, norovirus. β-lactam-resistant Enterobacterales infections. Infective endocarditis. Pneumonia. Sepsis and septic shock. Influenza vaccination. Recurrent urinary tract infection. Staphylococcus aureus (chemoprophylaxis in asymptomatic carriers). Venous catheter infection (prevention).
26.15 Apr 12
Changes in cefepime, dalbavancin, daptomycin, doxycycline, eravacycline, isavuconazole, linezolid, quinolones. Acinetobacter, Anaplasma, Bacillus spp, Bartonella, Borrelia burgdorferi, Corynebacterium, Mycoplasma spp, Stenotrophomonas, Treponema pallidum; Aspergillus, Candida, Coccidioides, Pneumocystis jirovecii, Rasamsonia; EBV, HBV, YFV. Brain abscess. Infectious endocarditis. Pancreatic infections. Lyme disease prevention.
26.14 Apr 5
Changes in ciprofloxacin, daptomycin, gepotidacin, oritavancin, quinolones, zoliflodacin. Helicobacter, Mycobacterium tuberculosis; Aspergillus, Schizophyllum; influenza. Infective endocarditis. Pleural effusion of infectious origin. Prosthetic joint infection. Sepsis and septic shock. Sinusitis. Toxic shock syndrome. Urethritis. Chikungunya vaccination. Infections associated with immunosuppressive therapies (prophylaxis). Infective endocarditis (prophylaxis). Staphylococcus aureus (chemoprophylaxis in asymptomatic carriers). Surgical site infection prevention.
26.13 Mar 29
Changes in dalbavancin. BCG, Clostridioides difficile, Enterococcus, Fusobacterium, Mycobacterium tuberculosis, Neisseria meningitidis, Roseomonas, Staphylococcus aureus; Candida; Trypanosoma cruzi. Biomarkers of inflammation/infection. Neutropenic enterocolitis. Pneumonia. Sepsis and septic shock. Vaginitis. Meningococcal meningitis (prevention). Recurrent vulvovaginal candidiasis. Surgical site infection (prophylaxis). Tuberculosis prevention.
26.12 Mar 23
• Inclusion of the tetanus severity score (TSS).
• Changes in carbapenems, cefepime, cefepime/enmetazobactam, faropenem, fostemsavir, gepotidacin, omadacycline, penicillins. Acinetobacter, Mycobacterium tuberculosis, Mycobacteroides chelonae, Pseudomonas aeruginosa, Streptococcus pneumoniae; Aspergillus, Candida, Cryptococcus neoformans, Mucor, Pneumocystis jirovecii, Trichophyton; HSV-1, SARS-CoV-2. Encephalitis. Infectious arthritis. Intravenous catheter infection. Neutropenic fever and in HSCT recipients. Pneumonia. Sepsis and septic shock. COVID-19 vaccination. Prophylaxis of invasive fungal disease. RSV vaccination. VEXAS syndrome (infection prevention).
26.11 Mar 14
• Inclusion of the SOFA-2 score (updated SOFA) and the AURIS score (C. auris candidemia).
• Changes in daptomycin, fluconazole, gentamicin, ibrexafungerp, isavuconazole, oteseconazole, posaconazole, sertaconazole, teicoplanin, voriconazole. Bacillus anthracis, Clostridioides difficile, Legionella, Mycobacteroides chelonae, Mycoplasma pneumoniae, Pluralibacter, Staphylococcus aureus, Treponema pallidum; Candida, Coccidioides, Gloniopsis, Talaromyces; Oestrus ovis. Pneumonia. Sepsis and septic shock. Vaginitis. Recurrent vulvovaginal candidiasis.
26.10 Mar 9
• Inclusion of a linezolid TDM predictive score for identifying out-of-range exposure risks.
• Changes in aztreonam/avibactam, dapsone, daptomycin, gepotidacin, itraconazole, meropenem, posaconazole, tecovirimat. Borrelia burgdorferi, Klebsiella, Lactobacillus, Leptospira, Mycobacterium leprae, Neisseria meningitidis, Staphylococcus aureus, Streptococcus agalactiae; Candida; HCV, HDV, MPXV. Exacerbations of COPD. Fever and rash. Odontogenic infections. Pharyngotonsillitis. Pneumonia. Sepsis and septic shock. Group B streptococcus (prevention of maternal and neonatal infection). Infections associated with immunosuppressive therapies (prophylaxis). RSV vaccination.
26.9 Mar 2
Changes in acyclovir, amikacin, ceftazidime/avibactam, zoliflodacin. Clostridium tetani, Cryptococcus neoformans, Franklinella schreckenbergeri, Legionella, Leptospira, Neisseria meningitidis, Spodiobacter cordis, Vandammella animalimorsus; Apophysomyces, Cunninghamella, Mucor, Pythium, Saksenaea; EBV, HIV, MPXV, RSV; Plasmodium spp. Allergy to antibiotics. Fever in neutropenic patients. Infections of the spine or spinal implants. Pyelonephritis. Sepsis and septic shock. Treatment of β-lactam-resistant Enterobacterales infections. HIV infection prophylaxis. Premature rupture of membranes (infection prevention). Surgical site infection prophylaxis. Tetanus vaccination.
26.8 Feb 23
• Inclusion of CAR-HEMATOTOX score.
• Changes in colistin, eravacycline, fosmanogepix, ECOFF values (erythromycin). Actinobacillus, Aggregatibacter, Capnocytophaga, Cardiobacterium, Chlamydia trachomatis, Chromobacterium, Dysgonomonas, Kingella, Klebsiella, Pasteurella, Pseudostreptobacillus hongkongensis, Streptobacillus moniliformis, Streptococcus suis, Suttonella indologenes; influenza; Leishmania spp. Bacterial prostatitis. Infectious arthritis. Pneumonia. Prosthetic joint infection. Pyelonephritis. Sepsis and septic shock. Exacerbations of COPD. Shingles vaccination. Surgical site infection prevention. Tuberculosis prevention.
26.7 Feb 16
Changes in cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam, colistin, moxifloxacin, rifampicin, temocillin. Campylobacter, Clostridioides difficile, Cutibacterium, Mycobacterium tuberculosis, Pseudomonas aeruginosa, rapidly growing mycobacteria, Staphylococcus aureus; Candida, Cryptococcus neoformans; EBV, influenza, Rocahepevirus ratti, TTV. Brain abscess. Fever in travelers returning from the tropics. Infectious adenitis. Infectious diarrhea. Pericarditis. Pneumonia. Vaginitis. HAV vaccination. Pneumonia associated with mechanical ventilation (prevention).
26.6 Feb 9
Changes in amphotericin B deoxycholate, cefepime, ceftaroline, eravacycline, lefamulin, rezafungin. Bordetella, Citrobacter, Mycoplasma pneumoniae, Pseudomonas aeruginosa, Streptococcus suis; Mucor; HSV, norovirus, SARS-CoV-2. Appendicitis. Biomarkers of inflammation/infection. Encephalitis. Treatment of β-lactam-resistant Enterobacterales infections. Tuberculosis prevention.
26.5 Feb 2
Changes in ceftolozane/tazobactam, monoclonal antibodies. CoNS, Mycobacterium tuberculosis, Proteus; Candida, Pichia, Yarrowia lipolytica; dengue, HBoV, HCV, VZV; Babesia, Sarcoptes scabiei, Strongyloides. Cardiac implantable electronic device infections. Exacerbations of COPD. Diabetic foot ulcer infections. Intravenous catheter infection. Myocarditis. Pericarditis. Pneumonia. Pyelonephritis. Sepsis and septic shock. Dengue vaccination. Infection in vaginal delivery (prevention). RSV vaccination.
26.4 Jan 26
Changes in acyclovir, amphotericin B deoxycholate, bacitracin, bedaquiline, cefepime, cefiderocol, ceftaroline, ceftriaxone, clofazimine, fluconazole, imipenem/relebactam, linezolid, meropenem, olorofim, omadacycline, piperacillin/tazobactam, teicoplanin. Enterococcus; Coccidioides, Fusarium; SFTSV, VZV. Fever in neutropenic patients. Pneumonia. Infections associated with immunosuppressive therapies (prophylaxis). Infections in neutropenic patients (prevention). Shingles vaccination.
26.3 Jan 19
• Updated EUCAST breakpoints (v16.0, January 2026) and ECOFF values.
• Changes in amphotericin B deoxycholate, caspofungin, ceftolozane/tazobactam, fluconazole, sulbactam/durlobactam, voriconazole. Clostridioides difficile, Enterococcus; BKPyV, CMV, EBV, HHV-6, HSV, JCPyV, VZV; Echinococcus multilocularis. Cystitis. Encephalitis. Fever in neutropenic patients. Infections of the eyelid, lacrimal system, conjunctiva, or cornea. Subacute or chronic meningitis. Treatment of β-lactam-resistant Enterobacterales infections.
26.2 Jan 12
Changes in carbapenems, cefepime/enmetazobactam, mecillinam. Acinetobacter, Enterococcus, Klebsiella, Streptococcus pyogenes; Candida; adenovirus, HHV-6, influenza, RSV; Leishmania, Loa loa, Schistosoma. Biomarkers of inflammation/infection. Diabetic foot ulcer infections. Encephalitis. Facial palsy. Infectious diarrhea. Infectious myelopathy. Infective endocarditis. Pneumonia. Pyelonephritis. Skin, subcutaneous tissue, and fascia infections. Recurrent urinary tract infection. VEXAS syndrome (infection prevention).
26.1 Jan 6
Changes in ceftibuten, cotrimoxazole, olorofim, trimethoprim. Helicobacter, Kingella, Klebsiella, Mycobacterium avium, Neisseria gonorrhoeae, Pseudomonas aeruginosa, Shigella; measles, SARS-CoV-2; Trypanosoma brucei. Biomarkers of inflammation/infection. Fever in neutropenic patients. Infections during CAR T-cell therapy. Infectious diarrhea. Infective endocarditis. IRIS. Pneumonia. Pyelonephritis. Infections associated with immunosuppressive therapies (prophylaxis). Infective endocarditis (prophylaxis). Surgical site infection prevention.
1.6.138 12/31/2025
Changes in cefiderocol, monoclonal antibodies, rifampicin. Klebsiella, Mycobacterium tuberculosis; Aspergillus; BKPyV, CMV, dengue, influenza, measles; Trypanosoma brucei. Abscesses: intra-abdominal, anorectal, and prostatic. Fever in neutropenic patients. Infections during CAR-T therapy. Infectious arthritis. Intravenous catheter infection. Sepsis and septic shock. Infections associated with immunosuppressive therapies (prophylaxis). Infections in CAR T-cell therapy (prevention). Infections in solid organ transplant recipients (prevention). Measles vaccination.
1.6.137 12/22/2025
• Inclusion of the Bacterial Meningitis Score (BMS).
• Changes in cefepime, cefpodoxime, daptomycin, olorofim. Klebsiella, Mycobacterium tuberculosis, Mycoplasma genitalium; Aspergillus; HPV. Appendicitis. Cardiac implantable electronic device infections. Fever in neutropenic patients. Infections during CAR-T. Infections of the spine. Osteomyelitis. Sepsis and septic shock. COVID-19 vaccination. HIV infection prophylaxis. Influenza vaccination. Surgical site infection prophylaxis.
1.6.136 12/16/2025
• Inclusion of the Fluoroquinolone Resistance Score (FQRS).
• Changes in aztreonam/avibactam. Acinetobacter, Borrelia burgdorferi, Helicobacter, Mycobacterium tuberculosis, Rickettsia spp, Staphylococcus aureus; Mucor; tick-borne encephalitis. Arthropod-borne infections. Cutaneous ulcer. Facial palsy. Fever in neutropenic patients. Infective endocarditis. Pneumonia. Sepsis and septic shock. Infections associated with immunosuppressive therapies (prophylaxis). RSV (prevention). Surgical site infection prevention.
1.6.135 12/08/2025
• Added Dermatophilus congolensis (under Pathogens).
• Changes in azithromycin, aztreonam/avibactam, cefepime/taniborbactam, cefiderocol, colistin, isoniazid. Enterobacter, Mycobacterium chelonae, Pseudomonas aeruginosa, Shigella, Streptococcus pneumoniae; CMV, EBOV, Mpox, SARS-CoV-2. Encephalitis. Exacerbations of COPD. Facial palsy. Peritonitis. Treatment of β-lactam-resistant Enterobacterales infections.
more Version 26.21 4d ago
Data Not Collected The developer does not collect any data from this app.
